ET. Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Media: Kristin Bhavnani Head of Global Corporate . Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. VP & Head of Investor Relations: N/A: N/A: N/A: Ms. Neena M. Patil J.D. Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Q2 2021 Earnings Conference Call August 3, 2021 4:30 PM ETCompany Participants. Learn about Jazz Pharmaceuticals PLC (JAZZ:XNAS) stock quote with Morningstar's rating and analysis and stay up to date with the current news, price, valuation, dividends and other stock . Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families . Vice President, Head, Investor Relations. DUBLIN, June 7, 2022-- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) . Katherine Littrell - Vice President, Investor Relations. Social Icons . Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. | May 24, 2022 Investor Home. Contents: Prepared Remarks; . Vice President, Head, Investor Relations. We are dedicated to developing life-changing . Corporate About Jazz Pharmaceuticals plc . We are dedicated to developing life-changing medicines for people with serious diseasesoften with limited or no therapeutic options. Investor Relations. Jazz Pharmaceuticals PLC (JAZZ) CEO Bruce Cozadd on Q3 2021 Results - Earnings Call Transcript. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. DUBLIN, June 29, 2018 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a definitive agreement to sell its rights related to Prialt (ziconotide) intrathecal infusion to TerSera Therapeutics LLC (TerSera) for $80 million in cash at closing. Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) Q3 2021 Earnings Call Nov 9, 2021, 4:30 p.m. DUBLIN, Oct. 26, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc today announced that it will report its 2021 third quarter financial results on Tuesday, November 9, 2021 after the close of the. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland +353 1 634 3211. Revenues came . Cantor Virtual Global Healthcare Conference on Monday . Ireland +353 1 634 3211. Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Our decades of proven success come from passionate team members around the globe collaborating to bring the . Asparaginase-associated toxicity in children with . Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. The Investor Relations website contains information about Jazz Pharmaceuticals plc's business for stockholders, potential investors, and financial analysts. Jazz Pharmaceuticals Contacts: Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations. 1 Hijiya N, van der Sluis IM. head of investor relations . ET. Contents: Prepared Remarks; . Investor Relations Jazz Pharmaceuticals PLC JAZZ Morningstar Rating Rating as of Mar 4, 2022. Learn about Jazz Pharmaceuticals PLC (JAZZ:XNAS) stock quote with Morningstar's rating and analysis and stay up to date with the current news, price, valuation, dividends and other stock . Media Contact: Kristin Bhavnani Head of . Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2019 Results Earnings Conference Call November 5, 2019 4:30 PM ETCompany Participants. Jazz Pharmaceuticals plc investorinfo@jazzpharma.com The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement . We are dedicated to developing life-changing medicines for people with serious diseases-often with limited or no therapeutic options. DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on . DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)-- Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced results from the recently completed Phase 1 clinical study of JZP-386, a deuterium-containing analog of sodium oxybate. Investors: Andrea N. Flynn, Ph.D.Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland +353 1 634 3211. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Quote Stock Analysis News Price vs Fair Value . Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Welcome to the Jazz Pharmaceuticals plc second-quarter 2019 earnings conference call. Home; . Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. Jazz Pharmaceuticals PLC - Stock Analysis. DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email protected] Ireland +353 1 634 3211 U.S. +1 650 496 2717. About Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the . Investor Relations. Corporate - Footer Links 1. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious . Image source: The Motley Fool. Jazz Pharmaceuticals plc. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland, +353 1 634 3211. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) issued its quarterly earnings results on Wednesday, May, 4th. BofA Virtual Global Healthcare Conference 2021 on Wednesday, September 15, 2021 . Supernus Support. Head of Investor Relations at Jazz Pharmaceuticals. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland +353 1 634 3211. Jazz Pharmaceuticals plc JAZZ is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. Vice President, Head, Investor Relations. Jazz Pharmaceuticals PLC ( JAZZ -2.04%) Q3 2021 Earnings Call. DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. PR Newswire. . SA Transcripts Tue, Nov. 09, 2021. Our current lead drug candidate, FT218, is . . Jazz Pharmaceuticals plc . . investorinfo@jazzpharma.com Ireland: +353 1 634 7892 U.S.: +1 650 496 2800. References: American Cancer Society. Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance. Rockville, MD 20850 (301) 838-2500. info@supernus.com. Rating as of May 6, 2022. Investor Relations Jazz Pharmaceuticals PLC . Jazz Pharmaceuticals plc (NASDAQ:NASDAQ:JAZZ) Q4 2020 Earnings Conference Call February 23, 2021 04:30 PM ET Company Participants Andrea Flynn - Head of Investor Relations Bruce Cozadd -. Morningstar Rating. Media: Kristin Bhavnani Head of Global Corporate . Bruce Cozadd - Chairman and Chief . InvestorInfo@jazzpharma.com. Media: Kristin Bhavnani Head of Global Corporate Communications Ireland +353 1 634 3211. ET. Jazz Pharmaceuticals plc. JAZZ Jazz Pharmaceuticals PLC Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance. ET / 7:00 p.m. IST in New York.. An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www . Key statistics for lung cancer. JAZZ. . Vice President, Head, Investor Relations Jazz Pharmaceuticals plc investorinfo@jazzpharma.com Ireland, +353 1 634 3211 U.S., +1 650 496 2717. 1-866-398-0833. Media: Jacqueline Kirby We'd be surprised if Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shareholders haven't noticed that an insider, Elmar Schnee, recently sold US$251k worth of stock at US$154 per . Print. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. DUBLIN, Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced Bruce Cozadd, chairman and chief executive officer, will present virtually as part of the 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, from 2:15 - 2:55 p.m. Jazz Pharmaceuticals PLC - Stock Analysis JAZZ. ET. Welcome to the Jazz Pharmaceuticals plc first-quarter 2019 earnings conference call. Jazz Pharmaceuticals plc. Investor Relations Jazz . Jazz Pharmaceuticals PLC (JAZZ 0.48%) Q4 2020 Earnings Call Feb 23, 2021, 4:30 p.m. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. By transforming biopharmaceutical discoveries into . Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small-cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute . Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and . . Media: Kristin Bhavnani Head of Global Corporate . Investors News Releases . Events and Presentations . Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families. Media: Jacqueline Kirby Vice President, Corporate Affairs & Government Relations Andrea Flynn - Investor Relations. Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy . Ms. Andrea N. Flynn Ph.D., VP & Head of Investor Relations; Ms. Neena M. Patil J.D., Chief Legal . ET / 8:40 p.m. IST in Las Vegas. DUBLIN, May 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2022 Global Healthcare Conference on Tuesday, May 10, 2022, at 12:40 p.m. PT / 3:40 p.m. References. Bruce . JAZZ earnings call for the period ending September 30, 2021. 1 Hijiya N, van der Sluis IM. . . Aug 13, 2021 7:07AM EDT. Investor Relations. DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 11:00 a.m. PT / 2:00 p.m. DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) . I will now turn the call over to Andrea Flynn, Head Investor Relations at Jazz Pharmaceuticals. The transaction is expected to close in the third quarter of 2018 and is subject . Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. Press Releases . Quote Stock Analysis News Price vs Fair Value Sustainability Trailing Returns Financials . In the coming days, we are showcasing our ongoing commitment to the sleep community with our presence at SLEEP 2022, the 36 th annual meeting of the Associated Professional Sleep Societies. An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www . The Investor Relations website contains information about Jazz Pharmaceuticals plc's business for stockholders, potential investors, and financial analysts. Jazz Pharmaceuticals PLC ( JAZZ 1.34%) Q1 2021 Earnings Call May 4, 2021, 4:30 p.m. Media: Kristin Bhavnani Head of Global Corporate Communications Jazz Pharmaceuticals plc . Media: Jacqueline Kirby Vice President, Corporate Affairs & Government Relations Skip to main navigation Top Bar Nav Contact Us. Jazz Pharmaceuticals and . This page shows recent SEC filings related to Jazz Pharmaceuticals PLC. Jazz Pharmaceuticals plc [email protected] Ireland +353 1 637 2141 U.S. +1 215 867 4948. DUBLIN, June 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, . It's been a good week for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shareholders, because the company has just released its latest yearly results, and the shares gained 7.4% to US$171. Printed . References. Today, Jazz . Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. . Consensus estimates suggest investors . Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. Jun 01, 2022, 4:15 PM ET. About Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the . and Investor Relations 781.674.5284 ir@concertpharma.com. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717 . Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. DUBLIN, Sept. 8, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences: . Provided by PR Newswire May 4, 2022 1:10 PM PDT. . ET / 7:00 p.m. IST in New York.. An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www . Nov 9, 2021, 4:30 p.m. [Operator instructions] I will now turn the call over to Kathee Littrell, head of investor relations at Jazz . We are focused on developing life-changing medicines for people with serious diseases often with limited or no options so they can live their lives more fully. Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. Investor and Media Overview. Ireland +353 1 634 . Jazz Investor Contact: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717 . Innovating to Transform the Lives of Those with Sleep Disorders. [Operator instructions] As a reminder, this conference call is being recorded. InvestorInfo@jazzpharma.com. DUBLIN, July 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 second quarter financia. ET / 7:00 p.m. IST in New York.. An audio webcast of the presentation will be available via the Investors section of the Jazz Pharmaceuticals website at www . Asparaginase-associated toxicity in children . The presentation will be available to registered conference attendees. Investor and Media Overview. The specialty pharmaceutical company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.13. Investor Relations. Supernus Pharmaceuticals, Inc. 9715 Key West Avenue. You may begin. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717 . Business Description. Media: Jacqueline Kirby Vice President, . SUPN Stock Price Today by TradingView. Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc [email . Media: Kristin Bhavnani Head of Global Corporate Communications Investors: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 2717. Thank you, and good afternoon, everyone. Thank . DUBLIN, Feb. 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc . ET / 7:15 - 7:55 p.m. GMT.. A live audio webcast of the presentation may be accessed from the Investors section . DUBLIN, April 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: . Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. InvestorInfo@jazzpharma.com. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products . At Jazz, our purpose is to innovate to transform the lives of patients and their families. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement . . Review quarterly and annual revenue, net income, and cash flow for Jazz Pharmaceuticals PLC (JAZZ:XMEX) stock through the last fiscal year. Jazz Pharmaceuticals PLC's Company Profile. Jazz Investor Contact: Andrea N. Flynn, Ph.D. Vice President, Head, Investor Relations Jazz Pharmaceuticals plc InvestorInfo@jazzpharma.com Ireland +353 1 634 3211 U.S. +1 650 496 .